Jefferson gets prostate test patent:
This article was originally published in Clinica
Executive Summary
Thomas Jefferson University in Philadelphia has received a US patent for a prostate cancer metastasis test. It is based on reverse transcriptase PCR and detects cells expressing prostate-specific antigen that are circulating in the blood. Such cells indicate that cancer has migrated from the prostate. Prostate cancer frequently metastasises to bones, making prostatectomy ineffective. Jefferson has licensed the test to UroCor for the US and Raggio-Italgene for Europe and Japan. UroCor is evaluating the test at eight cancer centres in the US.